Status:
COMPLETED
Eliquis Regulatory Post Marketing Surveillance (rPMS)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
19+ years
Brief Summary
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effecti...
Eligibility Criteria
Inclusion
- Signed data release
- Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty
Exclusion
- Being treated for an indication not approved for the use of Eliquis® in Korea
- Is contraindicated for the use of Eliquis® as described in the Korean label
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01885585
Start Date
July 1 2014
End Date
May 1 2015
Last Update
February 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Seoul, South Korea, 110-744